Future prospects and challenges of vaccines against filariasis

Parasite Immunology

Volumn 34, Issue 5, 2012, Pages 243-253

  Babayan, S A ^a   Allen, J E ^a   Taylor, D W ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Experimental models; Filariasis; Vaccine

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE; DNA VACCINE; DOXYCYCLINE; IVERMECTIN; TETRACYCLINE;

BANCROFTIAN FILARIASIS; BRUGIAN FILARIASIS; CATTLE; CELL ACTIVATION; COMA; DRUG FATALITY; ECOLOGY; EVOLUTION; GENE SEQUENCE; GENETIC ENGINEERING AND GENE TECHNOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LITOMOSOIDES SIGMODONTIS; LOIASIS; LYMPHATIC FILARIASIS; NONHUMAN; ONCHOCERCIASIS; PRIORITY JOURNAL; REVIEW; RODENT; SINGLE DRUG DOSE; SYSTEMS BIOLOGY; TH1 TH2 BALANCE; TH2 CELL; VACCINATION;

ANIMALS; ANTIGENS, HELMINTH; BRUGIA MALAYI; DRUG DISCOVERY; FILARIASIS; HUMANS; ONCHOCERCA VOLVULUS; SYSTEMS BIOLOGY; VACCINES; WUCHERERIA BANCROFTI;

ANIMALIA; BRUGIA MALAYI; ONCHOCERCA VOLVULUS; WUCHERERIA BANCROFTI;

EID: 84859492580     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2011.01350.x     Document Type: Review

References (110)

1. Ottesen EA, Hooper PJ, Bradley M & Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8years. PLoS Negl Trop Dis 2008; 2: e317.
2. Cupp EW, Sauerbrey M & Richards F. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan((R))) monotherapy. Acta Trop 2011; 120(Suppl 1): S100-S108.
3. Sékétéli A, Adeoye G, Eyamba A, et al. The achievements and challenges of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 2002; 96: 15-28.
4. Taylor MJ, Hoerauf A & Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 2010; 376: 1175-1185.
5. Le GL, Marechal P, Petit G, Taylor DW, Hoffmann W & Bain O. Early reduction of the challenge recovery rate following immunization with irradiated infective larvae in a filaria mouse system. Trop Med Int Health 1997; 2: 1170-1174.
6. Babayan SA, Attout T, Harris A, et al. Vaccination against filarial nematodes with irradiated larvae provides long-term protection against the third larval stage but not against subsequent life cycle stages. Int J Parasitol 2006; 36: 903-914.
7. Anand SB, Kodumudi KN, Reddy MV & Kaliraj P. A combination of two Brugia malayi filarial vaccine candidate antigens (BmALT-2 and BmVAH) enhances immune responses and protection in jirds. J Helminthol 2011; 85: 442-452.
8. Bockarie MJ & Deb RM. Elimination of lymphatic filariasis: do we have the drugs to complete the job? Curr Opin Infect Dis 2010; 23: 617-620.
9. Hoerauf A, Pfarr K, Mand S, Debrah AY & Specht S. Filariasis in Africa - treatment challenges and prospects. Clin Microbiol Infect 2011; 17: 977-985.
10. Zoure HG, Wanji S, Noma M, et al. The geographic distribution of Loa loa in Africa: Results of large-scale implementation of the rapid assessment procedure for loiasis (RAPLOA). PLoS Negl Trop Dis 2011; 5: e1210.
11. Boussinesq M, Gardon J, Gardon-Wendel N & Chippaux JP. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2003; 2(Suppl 1): S4.
12. Ardelli BF & Prichard RK. Reduced genetic variation of an Onchocerca volvulus ABC transporter gene following treatment with ivermectin. Trans R Soc Trop Med Hyg 2007; 101: 1223-1232.
13. Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO & Prichard RK. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis 2011; 5: e998.
14. Langworthy NG, Renz A, Mackenstedt U, et al. Macrofilaricidal activity of tetracycline against the filarial nematode Onchocerca ochengi: elimination of Wolbachia precedes worm death and suggests a dependent relationship. Proc Biol Sci 2000; 267: 1063-1069.
15. Ferri E, Bain O, Barbuto M, et al. New insights into the evolution of Wolbachia infections in filarial nematodes inferred from a large range of screened species. PLoS ONE 2011; 6: e20843.
16. McGarry HF, Pfarr K, Egerton G, et al. Evidence against Wolbachia symbiosis in Loa loa. Filaria J 2003; 2: 9.
17. Hoerauf A, Specht S, Buttner M, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol 2008; 197: 295-311.
18. Turner JD, Tendongfor N, Esum M, et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial. PLoS Negl Trop Dis 2010; 4: e660.
19. Bockarie MJ, Taylor MJ & Gyapong JO. Current practices in the management of lymphatic filariasis. Expert Rev Anti Infect Ther 2009; 7: 595-605.
20. Gyapong JO, Kumaraswami V, Biswas G & Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005; 6: 179-200.
21. WHO. Working to Overcome the Global Impact of Neglected Tropical Diseases: First WHO Report on Neglected Tropical Diseases 2010. Geneva: World Health Organization, 2011:150.
22. Supali T, Djuardi Y, Pfarr KM, et al. Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin Infect Dis 2008; 46: 1385-1393.
23. Debrah AY, Mand S, Specht S, et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2006; 2: e92.
24. Mand S, Pfarr K, Sahoo PK, et al. Macrofilaricidal activity and amelioration of lymphatic pathology in bancroftian filariasis after 3weeks of doxycycline followed by single-dose diethylcarbamazine. Am J Trop Med Hyg 2009; 81: 702-711.
25. Dadzie Y, Neira M & Hopkins D. Final report of the Conference on the eradicability of Onchocerciasis. Filaria J 2003; 2: 2.
26. Diawara L, Traore MO, Badji A, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009; 3: e497.
27. Brattig NW. Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Microbes Infect 2004; 6: 113-128.
28. Pfarr KM, Debrah AY, Specht S & Hoerauf A. Filariasis and lymphoedema. Parasite Immunol 2009; 31: 664-672.
29. Maizels RM & Yazdanbakhsh M. Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol 2003; 3: 733-744.
30. Adjobimey T & Hoerauf A. Induction of immunoglobulin G4 in human filariasis: an indicator of immunoregulation. Ann Trop Med Parasitol 2010; 104: 455-464.
31. Hoerauf A & Brattig N. Resistance and susceptibility in human onchocerciasis ? beyond Th1 vs Th2. Trends Parasitol 2002; 18: 25-31.
32. Turaga PS, Tierney TJ, Bennett KE, et al. Immunity to onchocerciasis: cells from putatively immune individuals produce enhanced levels of interleukin-5, gamma interferon, and granulocyte-macrophage colony-stimulating factor in response to Onchocerca volvulus larval and male worm antigens. Infect Immun 2000; 68: 1905-1911.
33. Doetze A. Production of both IFN-gamma and IL-5 by Onchocerca volvulus S1 antigen- specific CD4+ T cells from putatively immune individuals. Int Immunol 1997; 9: 721-729.
34. Elson LH, Calvopina HM, Paredes YW, et al. Immunity to onchocerciasis: putative immune persons produce a Thl-like response to Onchocerca volvulus. J Infect Dis 1995; 171: 652-658.
35. Soboslay PT, Geiger SM, Weiss N, et al. The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection. Immunology 1997; 90: 592-599.
36. Nielsen NO, Bloch P & Simonsen PE. Lymphatic filariasis-specific immune responses in relation to lymphoedema grade and infection status. II. Humoral responses. Trans R Soc Trop Med Hyg 2002; 96: 453-458.
37. Nielsen NO, Bloch P & Simonsen PE. Lymphatic filariasis-specific immune responses in relation to lymphoedema grade and infection status. I. Cellular responses. Trans R Soc Trop Med Hyg 2002; 96: 446-452.
38. Trees AJ, Wahl G, Kläger S & Renz A. Age-related differences in parasitosis may indicate acquired immunity against microfilariae in cattle naturally infected with Onchocerca ochengi. Parasitology 1992; 104: 247.
39. Wahl G, Achu-Kwi MD, Mbah D, Dawa O & Renz A. Bovine onchocercosis in north Cameroon. Vet Parasitol 1994; 52: 297-311.
40. Xie H, Bain O & Williams SA. Molecular phylogenetic studies on filarial parasites based on 5S ribosomal spacer sequences. Parasite 1994; 1: 141-151.
41. Wahl G, Enyong P, Ngosso A, et al. Onchocerca ochengi: epidemiological evidence of cross-protection against Onchocerca volvulus in man. Parasitology 1998; 116: 349-362.
42. Seidenfaden R, Fischer A, Bonow I, Ekale D, Tanya V & Renz A. Combined benefits of annual mass treatment with ivermectin and cattle zooprophylaxis on the severity of human onchocerciasis in northern Cameroon. Trop Med Int Health 2001; 6: 715-725.
43. Trees AJ. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the rapid assessment procedure for loiasis (raploa). Parasitology Today 1992; 8: 337-339.
44. Achukwi MD, Harnett W, Enyong P & Renz A. Successful vaccination against Onchocerca ochengi infestation in cattle using live Onchocerca volvulus infective larvae. Parasite Immunol 2007; 29: 113-116.
45. Tchakoute VL, Graham SP, Jensen SA, et al. In a bovine model of onchocerciasis, protective immunity exists naturally, is absent in drug-cured hosts, and is induced by vaccination. Proc Natl Acad Sci USA 2006; 103: 5971-5976.
46. Graham SP, Trees AJ, Collins RA, et al. Down-regulated lymphoproliferation coincides with parasite maturation and with the collapse of both gamma interferon and interleukin-4 responses in a bovine model of onchocerciasis. Infect Immun 2001; 69: 4313-4319.
47. Nfon CK, Makepeace BL, Njongmeta LM, Tanya VN, Bain O & Trees AJ. Eosinophils contribute to killing of adult Onchocerca ochengi within onchocercomata following elimination of Wolbachia. Microbes Infect 2006; 8: 2698-2705.
48. Jarrett WF, Jennings FW, McIntyre WI, Mulligan W & Urquhart GM. Irradiated helminth larvae in vaccination. Proc R Soc Med 1958; 51: 743-744.
49. Bickle QD. Radiation-attenuated schistosome vaccination - a brief historical perspective. Parasitology 2009; 136: 1621-1632.
50. Schrempf-Eppstein B, Kern A, Textor G & Lucius R. Acanthocheilonema viteae: vaccination with irradiated L3 induces resistance in three species of rodents (Meriones unguiculatus, Mastomys coucha, Mesocricetus auratus). Trop Med Int Health 1997; 2: 104-110.
51. Lange AM, Yutanawiboonchai W, Lok JB, Trpis M & Abraham D. Induction of protective immunity against larval Onchocerca volvulus in a mouse model. Am J Trop Med Hyg 1993; 49: 783-788.
52. Osborne J. The L3 of Brugia induces a Th2-polarized response following activation of an IL-4-producing CD4-CD8- alphabeta T cell population. Int Immunol 1998; 10: 1583-1590.
53. Carlow CK & Bianco AE. Transfer of immunity to the microfilariae of Onchocerca lienalis in mice. Trop Med Parasitol 1987; 38: 283-286.
54. Abraham D, Leon O, Schnyder-Candrian S, et al. Immunoglobulin E and eosinophil-dependent protective immunity to larval Onchocerca volvulus in mice immunized with irradiated larvae. Infect Immun 2004; 72: 810-817.
55. Hartmann S, Sollwedel A, Hoffmann A, Sonnenburg B & Lucius R. Characterization of IgE responses in a rodent model of filariasis and the allergenic potential of filarial antigens using an in vitro assay. Parasite Immunol 2003; 25: 9-16.
56. Baldwin CI, de Medeiros F & Denham DA. IgE responses in cats infected with Brugia pahangi. Parasite Immunol 1993; 15: 291-296.
57. Petit G, Diagne M, Marechal P, Owen D, Taylor D & Bain O. Maturation of the filaria Litomosoides sigmodontis in BALB/c mice; comparative susceptibility of nine other inbred strains. Ann Parasitol Hum Comp 1992; 67: 144-150.
58. Graham AL, Taylor MD, Le Goff L, Lamb TJ, Magennis M & Allen JE. Quantitative appraisal of murine filariasis confirms host strain differences but reveals that BALB/c females are more susceptible than males to Litomosoides sigmodontis. Microbes Infect 2005; 7: 612-618.
59. Le Goff L, Lamb TJ, Graham AL, Harcus Y & Allen JE. IL-4 is required to prevent filarial nematode development in resistant but not susceptible strains of mice. Int J Parasitol 2002; 32: 1277-1284.
60. Al-Qaoud K. The Xid defect imparts susceptibility to experimental murine filariosis - association with a lack of antibody and IL-10 production by B cells in response to phosphorylcholine. Int Immunol 1998; 10: 17-25.
61. Volkmann L, Saeftel M, Bain O, Fischer K, Fleischer B & Hoerauf A. Interleukin-4 is essential for the control of microfilariae in murine infection with the filaria Litomosoides sigmodontis. Infect Immun 2001; 69: 2950-2956.
62. Lawrence RA. Immunity to filarial nematodes. Vet Parasitol 2001; 100: 33-44.
63. Hoffmann WH, Pfaff AW, Schulz-Key H & Soboslav PT. Determinants for resistance and susceptibility to microfilaraemia in Litomosoides sigmodontis filariasis. Parasitology 2001; 122: 641-649.
64. Allen JE & Maizels RM. Diversity and dialogue in immunity to helminths. Nat Rev Immunol 2011; 11: 375-388.
65. Taylor MD, van der Werf N, Harris A, et al. Early recruitment of natural CD4+Foxp3+ Treg cells by infective larvae determines the outcome of filarial infection. Eur J Immunol 2009; 39: 192-206.
66. Taylor MD, LeGoff L, Harris A, Malone E, Allen JE & Maizels RM. Removal of regulatory T cell activity reverses hyporesponsiveness and leads to filarial parasite clearance in vivo. J Immunol 2005; 174: 4924-4933.
67. Le Goff L, Martin C, Oswald IP, et al. Parasitology and immunology of mice vaccinated with irradiated Litomosoides sigmodontis larvae. Parasitology 2000; 120: 271-280.
68. Wagner U, Hirzmann J, Hintz M, et al. Characterization of the DMAE-modified juvenile excretory-secretory protein Juv-p120 of Litomosoides sigmodontis. Mol Biochem Parasitol 2011; 176: 80-89.
69. Martin C, Saeftel M, Vuong PN, et al. B-cell deficiency suppresses vaccine-induced protection against murine filariasis but does not increase the recovery rate for primary infection. Infect Immun 2001; 69: 7067-7073.
70. Martin C, Al-Qaoud KM, Ungeheuer MN, et al. IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. Med Microbiol Immunol 2000; 189: 67-74.
71. Martin C, Le Goff L, Ungeheuer MN, Vuong PN & Bain O. Drastic reduction of a filarial infection in eosinophilic interleukin-5 transgenic mice. Infect Immun 2000; 68: 3651-3656.
72. Bleiss W, Oberländer U, Hartmann S, et al. Onchocerca ochengi: Mimic, model or modulator of O. volvulus? J Parasitol 2002; 88: 264-270.
73. Pfaff AW, Schulz-Key H, Soboslay PT, Geiger SM & Hoffmann WH. The role of nitric oxide in the innate resistance to microfilariae of Litomosoides sigmodontis in mice. Parasite Immunol 2000; 22: 397-405.
74. Gray CA & Lawrence RA. Interferon-gamma and nitric oxide production are not required for the immune-mediated clearance of Brugia malayi microfilariae in mice. Parasite Immunol 2002; 24: 329-336.
75. Volkmann L, Bain O, Saeftel M, et al. Murine filariasis: interleukin 4 and interleukin 5 lead to containment of different worm developmental stages. Med Microbiol Immunol 2003; 192: 23-31.
76. Specht S, Volkmann L, Wynn T & Hoerauf A. Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in murine filariasis. Infect Immun 2004; 72: 6287-6293.
77. Devaney E, Gillan V, Wheatley I, Jenson J, O'Connor R & Balmer P. Interleukin-4 influences the production of microfilariae in a mouse model of Brugia infection. Parasite Immunol 2002; 24: 29-37.
78. Gray CA & Lawrence RA. A role for antibody and Fc receptor in the clearance of Brugia malayi microfilariae. Eur J Immunol 2002; 32: 1114-1120.
79. Kalyanasundaram R & Balumuri P. Multivalent vaccine formulation with BmVAL-1 and BmALT-2 confer significant protection against challenge infections with Brugia malayi in mice and jirds. Res Rep Trop Med 2011; 2011: 45-56.
80. Makepeace BL, Jensen SA, Laney SJ, et al. Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure. PLoS Negl Trop Dis 2009; 3: e544.
81. Babayan SA, Read AF, Lawrence RA, Bain O & Allen JE. Filarial parasites develop faster and reproduce earlier in response to host immune effectors that determine filarial life expectancy. PLoS Biol 2010; 8: e1000525.
82. Dittrich AM, Erbacher A, Specht S, et al. Helminth infection with Litomosoides sigmodontis induces regulatory T cells and inhibits allergic sensitization, airway inflammation, and hyperreactivity in a murine asthma model. J Immunol 2008; 180: 1792-1799.
83. Hoerauf A, Satoguina J, Saeftel M & Specht S. Immunomodulation by filarial nematodes. Parasite Immunol 2005; 27: 417-429.
84. Schneider DS & Ayres JS. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat Rev Immunol 2008; 8: 889-895.
85. Bethony JM, Simon G, Diemert DJ, et al. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults. Vaccine 2008; 26: 2408-2417.
86. Hotez PJ, Bethony JM, Diemert DJ, Pearson M & Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010; 8: 814-826.
87. Paul WE & Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol 2010; 10: 225-235.
88. Phythian-Adams AT, Cook PC, Lundie RJ, et al. CD11c depletion severely disrupts Th2 induction and development in vivo. J Exp Med 2010; 207: 2089-2096.
89. MacDonald AS & Maizels RM. Alarming dendritic cells for Th2 induction. J Exp Med 2008; 205: 13-17.
90. Pulendran B & Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011; 12: 509-517.
91. Schierack P, Lucius R, Sonnenburg B, Schilling K & Hartmann S. Parasite-specific immunomodulatory functions of filarial cystatin. Infect Immun 2003; 71: 2422-2429.
92. Manoury B, Gregory WF, Maizels RM & Watts C. Bm-CPI-2, a cystatin homolog secreted by the filarial parasite Brugia malayi, inhibits class II MHC-restricted antigen processing. Curr Biol 2001; 11: 447-451.
93. Nchinda G, Kuroiwa J, Oks M, et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 2008; 118: 1427-1436.
94. Oberg AL, Kennedy RB, Li P, Ovsyannikova IG & Poland GA. Systems biology approaches to new vaccine development. Curr Opin Immunol 2011; 23: 436-443.
95. Friedel CC & Haas J. Virus-host interactomes and global models of virus-infected cells. Trends Microbiol 2011; 19: 501-508.
96. Rodland KD, Adkins JN, Ansong C, et al. Use of high-throughput mass spectrometry to elucidate host-pathogen interactions in Salmonella. Future Microbiol 2008; 3: 625-634.
97. McDermott JE, Yoon H, Nakayasu ES, et al. Technologies and approaches to elucidate and model the virulence program of salmonella. Front Microbiol 2011; 2: 121.
98. Gandon S, Jansen VA & van Baalen M. Host life history and the evolution of parasite virulence. Evolution 2001; 55: 1056-1062.
99. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK & Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-1946.
100. Day T, Galvani A, Struchiner C & Gumel A. The evolutionary consequences of vaccination. Vaccine 2008; 26: C1-C3.
101. Lynch PA, Grimm U & Read AF. How will public and animal health interventions drive life-history evolution in parasitic nematodes? Parasitology 2008; 135: 1599-1611.
102. Lazarus R, Vercelli D, Palmer LJ, et al. Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunol Rev 2002; 190: 9-25.
103. Carvalho A, Cunha C, Pasqualotto AC, Pitzurra L, Denning DW & Romani L. Genetic variability of innate immunity impacts human susceptibility to fungal diseases. Int J Infect Dis 2010; 14: e460-e468.
104. Pedersen AB & Babayan SA. Wild immunology. Mol Ecol 2011; 20: 872-880.
105. Babu S, Bhat SQ, Kumar NP, et al. Attenuation of toll-like receptor expression and function in latent tuberculosis by coexistent filarial infection with restoration following antifilarial chemotherapy. PLoS Negl Trop Dis 2009; 3: e489.
106. Nookala S, Srinivasan S, Kaliraj P, Narayanan RB & Nutman TB. Impairment of tetanus-specific cellular and humoral responses following tetanus vaccination in human lymphatic filariasis. Infect Immun 2004; 72: 2598-2604.
107. Thirugnanam S, Pandiaraja P, Ramaswamy K, et al. Brugia malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model. Exp Parasitol 2007; 116: 483-491.
108. Anand SB, Murugan V, Prabhu PR, Anandharaman V, Reddy MV & Kaliraj P. Comparison of immunogenicity, protective efficacy of single and cocktail DNA vaccine of Brugia malayi abundant larval transcript (ALT-2) and thioredoxin peroxidase (TPX) in mice. Acta Trop 2008; 107: 106-112.
109. Rathaur S, Yadav M, Gupta S, Anandharaman V & Reddy MV. Filarial glutathione-S-transferase: a potential vaccine candidate against lymphatic filariasis. Vaccine 2008; 26: 4094-4100.
110. McCarthy JS, Wieseman M, Tropea J, et al. Onchocerca volvulus glycolytic enzyme fructose-1, 6-bisphosphate aldolase as a target for a protective immune response in humans. Infect Immun 2002; 70: 851-858.